Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01182233 | Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation | terminated | Phase 1 | 4 | University of RochesterOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00512460 | RTA 744 Injection in Patients With Leptomeningeal Disease | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT01807286 |
| Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis |
| terminated |
| Phase 1 |
| 3 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| May 13, 2016 |
| clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy | terminated | Phase 1 / Phase 2 | 62 | CephalonINDUSTRY | 1 | Apr 11, 2016 | clinicaltrials |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 4 | Apr 5, 2016 | clinicaltrials |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 25 | Akinion Pharmaceuticals ABINDUSTRY | 4 | Mar 25, 2016 | clinicaltrials |
| NCT01455025 | Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia(PRIMAL) | terminated | Phase 1 | 11 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT00664586 | A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors | terminated | Phase 1 | 21 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | terminated | Phase 1 | 16 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT01604031 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide(TAIL) | terminated | Phase 1 | 2 | Baylor College of MedicineOTHER | 1 | Feb 8, 2016 | clinicaltrials |
| NCT02096341 | A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 | terminated | Phase 1 | 2 | EpicentRx, Inc.INDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT00660036 | Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia | terminated | Phase 1 | 5 | University of PittsburghOTHER | 1 | Jan 15, 2016 | clinicaltrials |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | terminated | Phase 1 / Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 22, 2015 | clinicaltrials |
| NCT01049113 | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | terminated | Phase 1 | 7 | Traws Pharma, Inc.INDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | SpirogenINDUSTRY | 1 | Nov 23, 2015 | clinicaltrials |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2015 | clinicaltrials |
| NCT00671112 | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | terminated | Phase 1 | 30 | Brian Hill, MD, PhDOTHER | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00577694 | Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 21 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00838890 | A Study of BMS-863233 in Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00860535 | Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) | terminated | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 30, 2015 | clinicaltrials |
| NCT00569179 | A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | terminated | Phase 1 | 1 | Indiana UniversityOTHER | 1 | Aug 31, 2015 | clinicaltrials |
| NCT00464113 | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia | terminated | Phase 1 | 49 | ExelixisINDUSTRY | 1 | Aug 21, 2015 | clinicaltrials |
| NCT00475917 | A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies | terminated | Phase 1 | 28 | ExelixisINDUSTRY | 1 | Aug 21, 2015 | clinicaltrials |
| NCT00526838 | Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies | terminated | Phase 1 | 84 | ExelixisINDUSTRY | 1 | Aug 21, 2015 | clinicaltrials |
| NCT00595829 | A Phase 1 Study of XL019 in Adults With Polycythemia Vera | terminated | Phase 1 | 3 | ExelixisINDUSTRY | 1 | Aug 21, 2015 | clinicaltrials |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | terminated | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT00954005 | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma(R-GO) | terminated | Phase 1 / Phase 2 | 56 | German Low Grade Lymphoma Study GroupOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01489722 | Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients | terminated | Phase 1 | 55 | AstraZenecaINDUSTRY | 2 | Aug 11, 2015 | clinicaltrials |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00905398 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(ALLPhi) | terminated | Phase 1 / Phase 2 | 8 | Rony SchaffelOTHER | 0 | Jul 9, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT00800150 | Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment | terminated | Phase 1 | 6 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01397149 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | terminated | Phase 1 / Phase 2 | 4 | University of UlmOTHER | 2 | May 28, 2015 | clinicaltrials |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | terminated | Phase 1 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 27, 2015 | clinicaltrials |
| NCT01130688 | Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. | terminated | Phase 1 | 2 | University of Massachusetts, WorcesterOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00669890 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML(High Risk) | terminated | Phase 1 | 12 | New York Medical CollegeOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00127101 | An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) | terminated | Phase 1 | 23 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 21, 2015 | clinicaltrials |
| NCT01193491 | Dose Escalation of IPI-493 in Hematologic Malignancies | terminated | Phase 1 | 4 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00077961 | Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL | terminated | Phase 1 / Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 26, 2015 | clinicaltrials |
Data updated 23 days agoSource updated May 17, 2016source: clinicaltrials